Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Ebersberg – page 27

1 343 clinical trials in Ebersberg, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Ebersberg at a glance
1 343
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 343 trials in Ebersberg

Open in trial search

Study on the Effectiveness and Safety of Sonrotoclax and Zanubrutinib for Adults with Relapsed or Refractory Mantle Cell Lymphoma

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sonrotoclax
  • Sponsor:BeOne Medicines AG

Study on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on Inhaled Molgramostim for Children with Autoimmune Pulmonary Alveolar Proteinosis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Molgramostim
  • Sponsor:Savara ApS

Study on Ivosidenib for Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome with IDH1 Mutation After Stem Cell Transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Technische Universitat Dresden

Study Comparing BMS-986393 CAR T Cell Therapy to Standard Treatments for Adults with Relapsed or Refractory Multiple Myeloma Resistant to Lenalidomide

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Celgene Corp.

Study Comparing Duvelisib with Gemcitabine or Bendamustine for Patients with Relapsed or Resistant T Cell Lymphoma Originating from T Follicular Helper Cells

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Duvelisib
  • Sponsor:Secura Bio Limited

Study on the Effectiveness and Safety of Sepofarsen for Patients with Leber Congenital Amaurosis Due to a Specific Genetic Mutation

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Sepofarsen
  • Sponsor:Laboratoires Thea

Study on Osimertinib and Chemotherapy for Stage IV Non-Small Cell Lung Cancer with Atypical EGFR Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Heidelberg University

Study on the Safety and Effectiveness of CRN04894 for Patients with Congenital Adrenal Hyperplasia

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atumelnant
  • Sponsor:Crinetics Pharmaceuticals Inc.

Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:University Of Cologne

Pancreatectomy

Recruiting

Study on Hydrocortisone for Patients Undergoing Pancreatic Surgery

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Hydrocortisone
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Study Comparing Amivantamab and Drug Combination for Patients with Recurrent or Metastatic Colorectal Cancer Without KRAS/NRAS and BRAF Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Ebersberg

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on triple-negative breast cancer treatment, evaluating the effectiveness of combining immunotherapy with conventional chemotherapy approaches.

  • Neoadjuvant Chemotherapy Studies
  • Immunotherapy Integration
  • Event-free Survival Assessment

Research aims to enhance treatment outcomes through targeted therapeutic combinations.

02 Genetic-Based Treatment

Studies examining treatment efficacy in patients with BRCA mutations, specifically targeting high-risk HER2-negative breast cancer cases.

  • Adjuvant Therapy Development
  • Invasive Disease Management
  • Targeted Treatment Approaches

Focused on improving survival rates through genetically-informed treatment strategies.

03 Hormone Receptor Research

Investigation of advanced treatment protocols for HR+/HER2- early breast cancer, combining endocrine therapy with innovative therapeutic agents.

  • Long-term Endocrine Therapy
  • Combination Treatment Protocols
  • Disease-free Survival Studies

Evaluating enhanced treatment strategies for hormone-responsive breast cancers.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.